These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38049334)

  • 1. [Characteristics and impact factors of SARS-CoV-2 infection in adult patients with relapsed/refractory B-cell non-Hodgkin lymphoma receiving chimeric antigen receptor T-cell therapy].
    Ge T; Liu H; Wang ZH; Cao Y; Zhang YC; Huang L; Qian WB; Zhou XX
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):825-831. PubMed ID: 38049334
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients.
    Mushtaq MU; Shahzad M; Chaudhary SG; Luder M; Ahmed N; Abdelhakim H; Bansal R; Balusu R; DeJarnette S; Divine C; Kribs R; Shune L; Singh AK; Ganguly S; Abhyankar SH; McGuirk JP
    Transplant Cell Ther; 2021 Sep; 27(9):796.e1-796.e7. PubMed ID: 34256172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SARS-CoV-2 infections in pediatric and young adult recipients of chimeric antigen receptor T-cell therapy: an international registry report.
    McNerney KO; Richards RM; Aguayo-Hiraldo P; Calkoen FG; Talano JA; Moskop A; Balduzzi A; Krajewski J; Dave H; Vatsayan A; Callahan C; Liu H; Li Y; Davis KL; Maude SL
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36707090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.
    Zeng C; Cheng J; Li T; Huang J; Li C; Jiang L; Wang J; Chen L; Mao X; Zhu L; Lou Y; Zhou J; Zhou X
    Cytotherapy; 2020 Mar; 22(3):166-171. PubMed ID: 32063474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes and risk factors of SARS-CoV-2 omicron variant in B-cell lymphoma patients following CD19 targeted CAR-T therapy.
    Xiao X; Chen P; Zhong Y; Luo X; Liu Y; Lu Y; Jin X; Qian W; Han W; Liang A; Liu H
    Cancer Med; 2023 Nov; 12(22):20838-20846. PubMed ID: 37962082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infectious complications following CAR-t cell therapy for B cell non-Hodgkin lymphoma: a single-center experience and review of the literature.
    Mercadal S; Gomez CA; Lee CJ; Couriel DR
    Ann Hematol; 2023 Jul; 102(7):1837-1843. PubMed ID: 37246975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Analysis of the feasibility and prognostic value of circulating tumor DNA monitoring in detecting gene mutations in patients with diffuse large B-cell lymphoma receiving chimeric antigen receptor T-cell therapy].
    Zhou LH; Feng YQ; Hu YX; Huang H
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):805-812. PubMed ID: 38049331
    [No Abstract]   [Full Text] [Related]  

  • 8. Long-term efficacy of CAR-T cell therapy for patients with relapsed/refractory B cell non-Hodgkin lymphoma.
    Fu S; Hu Y; Huang H
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 51(2):167-174. PubMed ID: 36161292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
    Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
    Front Immunol; 2020; 11():564099. PubMed ID: 33329526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report.
    Madduri D; Parekh S; Campbell TB; Neumann F; Petrocca F; Jagannath S
    J Med Case Rep; 2021 Feb; 15(1):90. PubMed ID: 33608053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Long-term follow-up of humanized and murine CD19 CAR-T-cell therapy for B-cell acute lymphoblastic leukemia].
    Du MY; Zhang YQ; Liao DY; Xie W; Xiong W; Mei H; Hu Y
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):793-799. PubMed ID: 38049329
    [No Abstract]   [Full Text] [Related]  

  • 12. [Efficacy and safety analysis of the zanubrutinib-based bridging regimen in chimeric antigen receptor T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma].
    Lu Y; Liu H; Ye SG; Zhou LL; Luo X; Dang XY; Yuan XG; Qian WB; Liang AB; Li P
    Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):813-819. PubMed ID: 38049332
    [No Abstract]   [Full Text] [Related]  

  • 13. Impact of SCHOLAR-1 Criteria on Chimeric Antigen Receptor T Cell Therapy Efficacy in Aggressive B Lymphoma: A Real-World GELTAMO/GETH Study.
    Bastos-Oreiro M; Gutierrez A; Iacoboni G; López Corral L; Reguera JL; Abrisqueta P; Delgado J; Terol MJ; Hernani R; Martínez N; Ortíz V; Bailen R; Gomez-Centurión I; Caballero A; Sanz J; Guerra Domínguez L; Luzardo H; Mussetti A; Jiménez-Ubieto A; Sancho JM; Sureda A; Pérez A; Barba P; Kwon M; Martín García-Sancho A
    Transplant Cell Ther; 2023 Dec; 29(12):747.e1-747.e10. PubMed ID: 37659694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD19/CD22 Chimeric Antigen Receptor T Cell Cocktail Therapy following Autologous Transplantation in Patients with Relapsed/Refractory Aggressive B Cell Lymphomas.
    Cao Y; Xiao Y; Wang N; Wang G; Huang L; Hong Z; Meng L; Zhou X; Wang J; Yang Y; Xu H; Zhang S; Xiao M; Chen L; Zheng M; Li C; Mao X; Gu C; Zhang T; Zhang Y; Zhou J
    Transplant Cell Ther; 2021 Nov; 27(11):910.e1-910.e11. PubMed ID: 34425260
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of Multiple SARS-CoV-2 Vaccine Doses in Patients with B Cell Hematologic Malignancies Receiving Chimeric Antigen Receptor T Cell Therapy: A Contemporary Cohort Analysis.
    Abid MB; Rubin M; Szabo A; Longo W; Fenske TS; McCoy C; Lorge A; Abedin S; D'Souza A; Dhakal B; Shah NN; Hamadani M
    Transplant Cell Ther; 2024 Mar; 30(3):285-297. PubMed ID: 38142942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes in Hematopoietic Cell Transplant and Chimeric Antigen Receptor T-Cell Therapy Recipients With Pre-Cellular Therapy SARS-CoV-2 Infection.
    Nimgaonkar I; Yoke LH; Roychoudhury P; Flaherty PW; Oshima MU; Weixler A; Gauthier J; Greninger AL; Mielcarek M; Boeckh M; Liu C; Hill JA
    Clin Infect Dis; 2024 Jul; 79(1):86-95. PubMed ID: 38427848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of Chimeric Antigen Receptor T Cell Therapy in Clinical Practice for Relapsed/Refractory Aggressive B Cell Non-Hodgkin Lymphoma: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy.
    Jain T; Bar M; Kansagra AJ; Chong EA; Hashmi SK; Neelapu SS; Byrne M; Jacoby E; Lazaryan A; Jacobson CA; Ansell SM; Awan FT; Burns L; Bachanova V; Bollard CM; Carpenter PA; DiPersio JF; Hamadani M; Heslop HE; Hill JA; Komanduri KV; Kovitz CA; Lazarus HM; Serrette JM; Mohty M; Miklos D; Nagler A; Pavletic SZ; Savani BN; Schuster SJ; Kharfan-Dabaja MA; Perales MA; Lin Y
    Biol Blood Marrow Transplant; 2019 Dec; 25(12):2305-2321. PubMed ID: 31446199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of chimeric antigen receptor T cell therapy in relapsed/refractory diffuse large B-cell lymphoma with different HBV status: a retrospective study from a single center.
    Kong D; Ping N; Gao X; Zou R; Wang P; Wu D; Jin Z; Qu C
    Front Immunol; 2023; 14():1200748. PubMed ID: 37292195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).
    George P; Dasyam N; Giunti G; Mester B; Bauer E; Andrews B; Perera T; Ostapowicz T; Frampton C; Li P; Ritchie D; Bollard CM; Hermans IF; Weinkove R
    BMJ Open; 2020 Feb; 10(2):e034629. PubMed ID: 32041862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.